股东周志文及冯宇霞保证向本公司提供的信息真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： | 权益变动方向 | 比例增加□ | | 比例减少☑ | | --- | --- | --- | --- | | 权益变动前合计比例 | 32.27% | | | | 权益变动后合计比例 | 30.93% | | | | 本次变动是否违反已作出的 承诺、意向、计划 | 是□ | 否☑ | | | 是否触发强制要约收购义务 | 是□ | 否☑ | | 一、信息披露义务人及其一致行动人的基本信息 证券代码：603127 证券简称：昭衍新药 公告编号：2026-004 北京昭衍新药研究中心股份有限公司 关于持股 5%以上股东权益变动触及 1%刻度的提示性公告 1、身份类别 | | ☑控股股东/实际控制人及其一致行动人 | | --- | --- | | | □其他 5%以上大股东及其一致行动人 | | 投资者及其一致行动人的身份 | □合并口径第一大股东及其一致行动人（仅 | | | 适用于无控股股东、实际控制人） | | | □其他_ ...

证券代码：603127 证券简称：昭衍新药 公告编号：2026-004 关于持股 5%以上股东权益变动触及 1%刻度的提示性公告 股东周志文及冯宇霞保证向本公司提供的信息真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： | 权益变动方向 | 比例增加□ | | 比例减少☑ | | --- | --- | --- | --- | | 权益变动前合计比例 | 32.27% | | | | 权益变动后合计比例 | 30.93% | | | | 本次变动是否违反已作出的 承诺、意向、计划 | 是□ | 否☑ | | | 是否触发强制要约收购义务 | 是□ | 否☑ | | 一、信息披露义务人及其一致行动人的基本信息 1、身份类别 | | ☑控股股东/实际控制人及其一致行动人 | | --- | --- | | | □其他 5%以上大股东及其一致行动人 | | 投资者及其一致行动人的身份 | □合并口径第一大股东及其一致行动人（仅适 | | | 用于无控股股东、实际控制人） | | | □其他______________（请注明 ...

Core Viewpoint - Zhaoyan New Drug (603127) has seen its stock price increase by over 5%, currently trading at 25.74 HKD, with a transaction volume of 116 million HKD. The company has announced an annual performance forecast indicating a projected net profit attributable to shareholders of approximately 233 million to 349 million CNY for 2025, representing a year-on-year growth of about 214.0% to 371.0% [1] Group 1 - The increase in net profit is attributed to the rise in market prices of biological assets and the natural growth appreciation of the company's assets, which positively contributed to the fair value changes [1] - The contribution of fair value changes of biological assets to net profit is estimated to be around 452 million to 500 million CNY [1] Group 2 - Recent market reports indicate that the price of key species, such as the crab-eating macaque, has surged to 120,000 to 130,000 CNY within a month, with some scarce sources reported at 150,000 CNY, reflecting an increase of over 30% compared to two months ago [1]

Core Viewpoint - Zhaoyan New Drug (06127) has seen a stock price increase of over 5%, currently trading at 25.74 HKD, with a transaction volume of 116 million HKD, following the announcement of its annual performance forecast, which indicates a significant expected increase in net profit for 2025 [1] Group 1: Financial Performance - The company anticipates a net profit attributable to shareholders of approximately 233 million to 349 million RMB for 2025, representing a year-on-year growth of about 214.0% to 371.0% [1] - The increase in net profit is attributed to the rise in market prices of biological assets and the natural growth appreciation of its own assets, contributing positively to the company's performance [1] - The fair value change of biological assets is expected to contribute approximately 452 million to 500 million RMB to net profit [1] Group 2: Market Insights - A senior investment advisor from Yuekai Securities noted that the average consumption of monkeys for a new drug from laboratory to clinical stage is 60, with the dosage for macromolecular drugs potentially doubling [1] - Recent market reports indicate that the price of the core species, the crab-eating macaque, has surged to 120,000 to 130,000 RMB within a month, with some scarce sources reported at 150,000 RMB, reflecting a price increase of over 30% compared to two months ago [1]

Core Viewpoint - Zhaoyan New Drug (603127) expects a decline in revenue for 2025, while projecting significant growth in net profit and adjusted net profit [1] Revenue Forecast - The company anticipates achieving an operating revenue of approximately 1.573 billion to 1.738 billion yuan in 2025, representing a year-on-year decrease of about 13.9% to 22.1% [1] Profit Forecast - The expected net profit attributable to shareholders for 2025 is projected to be around 233 million to 349 million yuan, indicating a year-on-year increase of approximately 214.0% to 371.0% [1] - The forecast for net profit excluding non-recurring gains and losses is estimated to be between 246 million to 370 million yuan, reflecting a year-on-year increase of approximately 945.2% to 1467.7% [1] Performance Drivers - The primary reason for the performance changes is attributed to the increase in market prices of biological assets and the natural growth appreciation, which positively impacted the fair value [1] - However, the profitability contribution from laboratory services has declined due to intense competition in the industry, leading to a decrease in revenue and gross margin from performance contracts year-on-year [1]

每经AI快讯，昭衍新药(06127.HK)高开逾4%，截至发稿涨4.42%，报26港元，成交额140.92万港元。 ...

Core Viewpoint - Zhaoyan New Drug (06127) is expected to experience a decline in revenue for 2025, while net profit is projected to increase significantly, driven by changes in the fair value of biological assets and challenges in laboratory services [1][2]. Group 1: Revenue and Profit Projections - The company anticipates revenue for 2025 to be approximately RMB 1.573 billion to RMB 1.738 billion, representing a decrease of about RMB 280 million to RMB 446 million compared to the previous year, which is a year-on-year decline of approximately 13.9% to 22.1% [1]. - Net profit attributable to shareholders is expected to be around RMB 233 million to RMB 349 million for 2025, an increase of approximately RMB 159 million to RMB 275 million compared to the previous year, reflecting a year-on-year increase of about 214.0% to 371.0% [1]. - The net profit excluding non-recurring gains and losses is projected to be approximately RMB 246 million to RMB 370 million, which is an increase of about RMB 223 million to RMB 346 million year-on-year, indicating a substantial increase of approximately 945.2% to 1,467.7% [1]. Group 2: Contributions and Challenges - The positive change in the fair value of biological assets is expected to contribute approximately RMB 452 million to RMB 500 million to net profit [1]. - The laboratory services and other business segments are projected to incur a net loss of approximately RMB 2.06 billion to RMB 1.3 billion, indicating challenges in this area [1]. - The increase in the fair value of biological assets is driven by rising market prices and natural growth, positively impacting the company's performance [2]. - Despite stable operations in the laboratory, revenue and gross margin from contractual obligations have decreased year-on-year due to intense prior industry competition, leading to a decline in profit contribution from laboratory services [2].

Group 1 - Zhaoyan New Drug expects a net profit of approximately 233 million to 349 million yuan for 2025, representing a year-on-year increase of 214% to 371%, driven by rising market prices of biological assets and natural growth appreciation [1] - Kaiyin Technology has withdrawn its drug registration application for Peginterferon α-2 injection, resulting in a one-time asset impairment of 110 million yuan, significantly impacting its 2025 profit [2] - Qizheng Tibetan Medicine's subsidiary has received approval for its Shiwai Longdan Flower Capsule as a national second-level protected traditional Chinese medicine, providing a seven-year market exclusivity that will enhance its competitive position [3] Group 2 - GSK has reached a final agreement to acquire RAPT Therapeutics, focusing on innovative therapies for inflammation and immune diseases, with the deal expected to close in Q1 2026 [4] - Qilu Pharmaceutical has initiated a Phase I clinical trial for QLS5316, its first dual-target antibody-drug conjugate aimed at advanced solid tumors, marking a significant step in its innovation strategy [5]

Core Viewpoint - The company anticipates a decline in revenue for 2025 while projecting a significant increase in net profit compared to the previous year [2][4]. Revenue Forecast - The expected operating revenue for 2025 is approximately RMB 1,572.60 million to RMB 1,738.14 million, representing a decrease of about RMB 280.20 million to RMB 445.73 million, or a year-on-year decline of approximately 13.9% to 22.1% [2][4]. Net Profit Forecast - The projected net profit attributable to shareholders for 2025 is around RMB 232.61 million to RMB 348.92 million, which indicates an increase of approximately RMB 158.54 million to RMB 274.84 million, or a year-on-year increase of about 214.0% to 371.0% [2][4]. Adjusted Net Profit Forecast - The expected net profit attributable to shareholders after deducting non-recurring gains and losses is estimated to be between RMB 246.38 million and RMB 369.57 million, reflecting an increase of approximately RMB 222.81 million to RMB 345.99 million, or a year-on-year increase of about 945.2% to 1,467.7% [2][4]. Contribution from Biological Assets - The net profit contribution from the fair value changes of biological assets is estimated to be between RMB 451.91 million and RMB 499.48 million [4]. Laboratory Services Performance - The net profit from laboratory services and other businesses is projected to be between RMB -205.53 million and RMB -129.91 million [5][6]. Previous Year Performance - In the previous year, the company achieved operating revenue of RMB 2,018.33 million and a net profit attributable to shareholders of RMB 74.08 million [7]. Factors Influencing Performance - The increase in biological asset values due to market price rises and natural growth has positively impacted the company's performance. However, the laboratory services business has seen a decline in profit contribution due to intense industry competition affecting revenue and gross margins [8].

昭衍新药（603127）1月20日发布2025年业绩预增公告，预计实现净利润为2.33亿元~3.49亿元，净利润 同比增长214.00%~371.00%。 （文章来源：证券时报网） 证券时报·数据宝统计显示，昭衍新药今日收于40.25元，下跌3.89%，日换手率为2.53%，成交额为6.44 亿元，近5日下跌3.78%。通过对2025年业绩预增50%以上的个股走势进行统计发现，预告发布后当日股 价上涨的占比67.06%，股价发布当日股价涨停的有3家。预告发布后5日股价上涨的占比75.29%。 资金面上，该股今日主力资金净流出3339.00万元，近5日资金净流出2021.12万元。最新（1月19日）两 融余额4.25亿元，其中，融资余额4.19亿元，环比前一交易日增长1.02%，近5日融资余额累计增长 7.55%。（数据宝） ...